Recursion Pharmaceuticals Faces 33.5% Short Interest as ARK Holds Stake
Recursion Pharmaceuticals, Inc. Class A (NASDAQ:RXRX) faces heavy short interest with roughly 33.5% of outstanding shares sold short, placing it third among stocks flagged for elevated short positions. Despite the short pressure, the stock climbed 10.38% today to reach 4.36 USD.
The high concentration of short interest reflects significant bearish sentiment among traders, which can increase share price volatility. At the same time, the ARK Genomic Revolution ETF continues to hold its position in the artificial intelligence-focused biopharmaceutical company, signaling sustained institutional backing.
Wall Street analysts remain focused on price targets and anticipated volatility surrounding near-term earnings updates. Market participants will watch how forthcoming financial results influence short seller activity and institutional support.
Key points
- Recursion Pharmaceuticals, Inc. Class A (NASDAQ:RXRX) short interest stands at approximately 33.5% of shares outstanding.
- The company ranks third among stocks flagged for elevated short interest positions.
- ARK Genomic Revolution ETF maintains its holding in the AI-driven biopharmaceutical firm.
- Shares of RXRX rose 10.38% today to close at 4.36 USD.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the short interest in Recursion Pharmaceuticals stock?
Short interest in Recursion Pharmaceuticals, Inc. Class A is about 33.5% of shares outstanding, ranking third among flagged names with elevated short positions.
Does ARK ETF still hold Recursion Pharmaceuticals?
Yes, the ARK Genomic Revolution ETF maintains its position supporting the AI-driven biopharmaceutical company.
How did RXRX stock perform today?
Shares of Recursion Pharmaceuticals gained 10.38% to trade at 4.36 USD.